Cargando…
Identifying problematic drugs based on the characteristics of their targets
Identifying promising compounds during the early stages of drug development is a major challenge for both academia and the pharmaceutical industry. The difficulties are even more pronounced when we consider multi-target pharmacology, where the compounds often target more than one protein, or multipl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555035/ https://www.ncbi.nlm.nih.gov/pubmed/26388775 http://dx.doi.org/10.3389/fphar.2015.00186 |
_version_ | 1782388119578869760 |
---|---|
author | Lopes, Tiago J. S. Shoemaker, Jason E. Matsuoka, Yukiko Kawaoka, Yoshihiro Kitano, Hiroaki |
author_facet | Lopes, Tiago J. S. Shoemaker, Jason E. Matsuoka, Yukiko Kawaoka, Yoshihiro Kitano, Hiroaki |
author_sort | Lopes, Tiago J. S. |
collection | PubMed |
description | Identifying promising compounds during the early stages of drug development is a major challenge for both academia and the pharmaceutical industry. The difficulties are even more pronounced when we consider multi-target pharmacology, where the compounds often target more than one protein, or multiple compounds are used together. Here, we address this problem by using machine learning and network analysis to process sequence and interaction data from human proteins to identify promising compounds. We used this strategy to identify properties that make certain proteins more likely to cause harmful effects when targeted; such proteins usually have domains commonly found throughout the human proteome. Additionally, since currently marketed drugs hit multiple targets simultaneously, we combined the information from individual proteins to devise a score that quantifies the likelihood of a compound being harmful to humans. This approach enabled us to distinguish between approved and problematic drugs with an accuracy of 60–70%. Moreover, our approach can be applied as soon as candidate drugs are available, as demonstrated with predictions for more than 5000 experimental drugs. These resources are available at http://sourceforge.net/projects/psin/. |
format | Online Article Text |
id | pubmed-4555035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45550352015-09-18 Identifying problematic drugs based on the characteristics of their targets Lopes, Tiago J. S. Shoemaker, Jason E. Matsuoka, Yukiko Kawaoka, Yoshihiro Kitano, Hiroaki Front Pharmacol Pharmacology Identifying promising compounds during the early stages of drug development is a major challenge for both academia and the pharmaceutical industry. The difficulties are even more pronounced when we consider multi-target pharmacology, where the compounds often target more than one protein, or multiple compounds are used together. Here, we address this problem by using machine learning and network analysis to process sequence and interaction data from human proteins to identify promising compounds. We used this strategy to identify properties that make certain proteins more likely to cause harmful effects when targeted; such proteins usually have domains commonly found throughout the human proteome. Additionally, since currently marketed drugs hit multiple targets simultaneously, we combined the information from individual proteins to devise a score that quantifies the likelihood of a compound being harmful to humans. This approach enabled us to distinguish between approved and problematic drugs with an accuracy of 60–70%. Moreover, our approach can be applied as soon as candidate drugs are available, as demonstrated with predictions for more than 5000 experimental drugs. These resources are available at http://sourceforge.net/projects/psin/. Frontiers Media S.A. 2015-09-01 /pmc/articles/PMC4555035/ /pubmed/26388775 http://dx.doi.org/10.3389/fphar.2015.00186 Text en Copyright © 2015 Lopes, Shoemaker, Matsuoka, Kawaoka and Kitano. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lopes, Tiago J. S. Shoemaker, Jason E. Matsuoka, Yukiko Kawaoka, Yoshihiro Kitano, Hiroaki Identifying problematic drugs based on the characteristics of their targets |
title | Identifying problematic drugs based on the characteristics of their targets |
title_full | Identifying problematic drugs based on the characteristics of their targets |
title_fullStr | Identifying problematic drugs based on the characteristics of their targets |
title_full_unstemmed | Identifying problematic drugs based on the characteristics of their targets |
title_short | Identifying problematic drugs based on the characteristics of their targets |
title_sort | identifying problematic drugs based on the characteristics of their targets |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555035/ https://www.ncbi.nlm.nih.gov/pubmed/26388775 http://dx.doi.org/10.3389/fphar.2015.00186 |
work_keys_str_mv | AT lopestiagojs identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets AT shoemakerjasone identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets AT matsuokayukiko identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets AT kawaokayoshihiro identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets AT kitanohiroaki identifyingproblematicdrugsbasedonthecharacteristicsoftheirtargets |